HTS pipeline

Our screening pipeline is designed to deliver robust and reproducible results, providing deep insights into compound activity and biological relevance.

In the primary screen, up to 240.000 compounds are tested using a single assay readout at a standard concentration of 10 µM, typically identifying 500-1000 primary hits. These hits are then cherry-picked and re-tested in triplicate to confirm reproducibility and eliminate technical artifacts. To assess specificity and reduce false positives, we integrate counter-screening assays, which may include orthogonal assays (targeting the same biology with a different readout) and validation assays such as toxicity screens or controls using alternate cell lines. Next, confirmed hits (typically 100-200) are subjected to dose-response analysis across the original and all counter assays. Compounds that meet potency thresholds (e.g., IC₅₀ ≤ 1 µM) are repurchased and tested again to confirm structure-activity relationships (SAR). Validated hits can be further evaluated using profiling techniques, i.e., by the Cell Painting assay (>> LEARN MORE) to gain a broader understanding of the compounds´ cellular effects and possible off-targets.

This data-driven approach is complemented by integrated cheminformatic analysis workflows to support compound prioritization and/or optimization for downstream research (>> CHEMINFORMATICS). Once the validated hit set is refined to less than a dozen compounds, we provide milligram-scale quantities for the application in your biological system.